SURVYR

HUMA

Humacyte, Inc.
$0.47
+$0.02 (5.40%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-80%-56%-33%-9%+15%Oct 2025Oct 2026Apr 202652w high $1.7852w low $0.34
HUMASPY
Wall St. Highest PT $4.00 (+750.9%) Wall St. Avg PT $1.62 (+245.7%)
$0$2$3$4$5POC $1Hi $4Avg $2
Underwater Drawdown %Max DD -79.2%Current -72.3%
0.0%-79.2%
Relative Strength vs SPY-85.9% vs SPYUnderperforming
+107%0%-107%
1W
+$0.06 (14.38%)
1M
−$0.08 (14.06%)
3M
−$0.15 (24.78%)
6M
−$0.35 (42.67%)
YTD
−$0.49 (51.08%)
1Y
−$1.23 (72.35%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
6 analysts · mean score 1.83
1 = Strong Buy · 5 = Sell
Strong Buy117%
Buy350%
Hold233%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$0.47
Average target$1.62
+$1.15 (+245.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$0.50
Median$1.12
High$4.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-07 · Barclays started covering HUMA at Equal-Weight
Reiterated
2026-08-13 · Benchmark reiterated Speculative Buy on HUMA
Reiterated
2026-07-28 · BTIG reiterated Buy on HUMA
Reiterated
2026-06-17 · TD Cowen reiterated Buy on HUMA
Reiterated
2026-06-16 · BTIG reiterated Buy on HUMA
Reiterated
2026-06-11 · HC Wainwright & Co. reiterated Buy on HUMA
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$121.0M
P/E (next 12 months, estimated)-1.8
52-week range$0.34 – $1.78
Revenue growth (latest quarter vs a year ago)+34.9%
Dividend yieldNo dividend
Analyst consensusBuy (6)
Average analyst price target$1.62 (+246%)

What they do

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for HUMA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

HUMA earningsNext report in 15 days
Next report
Thu Nov 12, 2026Before the open
EPS consensus-$0.08 range -$0.10–-$0.06
Revenue consensus$770.0K 5 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026-$0.16est -$0.10−54.8%Below estimates
May 13, 2026-$0.09est -$0.11+21.7%Above estimates
Mar 27, 2026-$0.13est -$0.13+3.7%In line with estimates
Nov 12, 2025-$0.11est -$0.15+25.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 22:37:41 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.260.28
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$406.0K+34.9%
2026-03-31$495.0K–
2025-12-31$467.0K–
2025-09-30$753.0K–
2025-06-30$301.0K–

News & catalysts

More news
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
GlobeNewswire · Oct 23
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Zacks · Oct 21
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Zacks · Oct 19
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
GlobeNewswire · Oct 15
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks · Oct 13
Rating changes
Initiated
2026-10-07 · Barclays started covering HUMA at Equal-Weight
Reiterated
2026-08-13 · Benchmark reiterated Speculative Buy on HUMA
Reiterated
2026-07-28 · BTIG reiterated Buy on HUMA
Reiterated
2026-06-17 · TD Cowen reiterated Buy on HUMA
Reiterated
2026-06-16 · BTIG reiterated Buy on HUMA
Reiterated
2026-06-11 · HC Wainwright & Co. reiterated Buy on HUMA

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Jones Keith Anthony
Director · 2026-09-14
Buy
$5.6K
Jones Keith Anthony
Director · 2026-08-20
Buy
$6.9K
Jones Keith Anthony
Director · 2026-08-17
Buy
$17.8K
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-24 22:37:41 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026